Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Debra Patt"'
Autor:
John Virostko, Anna G. Sorace, Kalina P. Slavkova, Anum S. Kazerouni, Angela M. Jarrett, Julie C. DiCarlo, Stefanie Woodard, Sarah Avery, Boone Goodgame, Debra Patt, Thomas E. Yankeelov
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background The purpose of this study was to determine whether advanced quantitative magnetic resonance imaging (MRI) can be deployed outside of large, research-oriented academic hospitals and into community care settings to predict eventual
Externí odkaz:
https://doaj.org/article/82deaf63a0e6424a945d9c5d7d128036
Autor:
Kalina P. Slavkova, Julie C. DiCarlo, Anum S. Kazerouni, John Virostko, Anna G. Sorace, Debra Patt, Boone Goodgame, Thomas E. Yankeelov
Publikováno v:
Tomography, Vol 7, Iss 3, Pp 253-267 (2021)
This study characterizes the error that results when performing quantitative analysis of abbreviated dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data of the breast with the Standard Kety–Tofts (SKT) model and its Patlak variant.
Externí odkaz:
https://doaj.org/article/244a6d56c90448bab12b3edcaba5617e
Autor:
Angela M. Jarrett, David A. Hormuth, II, Chengyue Wu, Anum S. Kazerouni, David A. Ekrut, John Virostko, Anna G. Sorace, Julie C. DiCarlo, Jeanne Kowalski, Debra Patt, Boone Goodgame, Sarah Avery, Thomas E. Yankeelov
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 820-830 (2020)
The ability to accurately predict response and then rigorously optimize a therapeutic regimen on a patient-specific basis, would transform oncology. Toward this end, we have developed an experimental-mathematical framework that integrates quantitativ
Externí odkaz:
https://doaj.org/article/17a79e5efe4e466a8d55e196250c77f9
Autor:
Angela M. Jarrett, Danial Faghihi, David A. Hormuth, Ernesto A. B. F. Lima, John Virostko, George Biros, Debra Patt, Thomas E. Yankeelov
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 5, p 1314 (2020)
Optimal control theory is branch of mathematics that aims to optimize a solution to a dynamical system. While the concept of using optimal control theory to improve treatment regimens in oncology is not novel, many of the early applications of this m
Externí odkaz:
https://doaj.org/article/15ea1173593444fe830c27f394619e6a
Autor:
Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen K.L. Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
Publikováno v:
European Journal of Cancer. 184:48-59
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We rep
Autor:
Julie C. DiCarlo, Angela M. Jarrett, Anum S. Kazerouni, John Virostko, Anna Sorace, Kalina P. Slavkova, Stefanie Woodard, Sarah Avery, Debra Patt, Boone Goodgame, Thomas E. Yankeelov
Publikováno v:
Magnetic Resonance in Medicine. 89:1134-1150
A method is presented to select the optimal time points at which to measure DCE-MRI signal intensities, leaving time in the MR exam for high-spatial resolution image acquisition.Simplicial complexes are generated from the Kety-Tofts model pharmacokin
Autor:
José Baselga, Andrew Koustenis, Martin Frenzel, Denise A. Yardley, Esther Zamora, Joyce O'Shaughnessy, Clifford A. Hudis, Hans Wildiers, Debra Patt, Véronique Diéras, Javier Cortés, Hope S. Rugo, Sara M. Tolaney, Maura N. Dickler
Supplemental Figure 1. Study Design and Patient Disposition Supplemental Figure 2. Change in serum creatinine by visit Supplemental Figure 3. Change in blood urea nitrogen (BUN) by visit Supplemental Figure 4. Maximum observed value in cystatin C by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c79c5a83b7a7daad1f4634068fd8b447
https://doi.org/10.1158/1078-0432.22468395
https://doi.org/10.1158/1078-0432.22468395
Autor:
José Baselga, Andrew Koustenis, Martin Frenzel, Denise A. Yardley, Esther Zamora, Joyce O'Shaughnessy, Clifford A. Hudis, Hans Wildiers, Debra Patt, Véronique Diéras, Javier Cortés, Hope S. Rugo, Sara M. Tolaney, Maura N. Dickler
Supplemental Table 1. Post-discontinuation therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9935dfa4ebd65bb05f8542cd874cec7
https://doi.org/10.1158/1078-0432.22468389
https://doi.org/10.1158/1078-0432.22468389
Autor:
José Baselga, Andrew Koustenis, Martin Frenzel, Denise A. Yardley, Esther Zamora, Joyce O'Shaughnessy, Clifford A. Hudis, Hans Wildiers, Debra Patt, Véronique Diéras, Javier Cortés, Hope S. Rugo, Sara M. Tolaney, Maura N. Dickler
Purpose: The phase II MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor–positive (HR+), HER2− metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::034b8161c60a47be698f6b30bb02f65c
https://doi.org/10.1158/1078-0432.c.6526920
https://doi.org/10.1158/1078-0432.c.6526920
Autor:
José Baselga, Andrew Koustenis, Martin Frenzel, Denise A. Yardley, Esther Zamora, Joyce O'Shaughnessy, Clifford A. Hudis, Hans Wildiers, Debra Patt, Véronique Diéras, Javier Cortés, Hope S. Rugo, Sara M. Tolaney, Maura N. Dickler
Methods that support the supplemental data provided
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6459561877577139b536e7c67614780e
https://doi.org/10.1158/1078-0432.22468392.v1
https://doi.org/10.1158/1078-0432.22468392.v1